#United States #New York #Class Action #Securities Fraud #Savara Inc.

Investors Encouraged to Join Class Action Against Savara Inc.

On September 19, 2025, Levi & Korsinsky, LLP, a law firm well-known for representing shareholders, issued a notification to investors impacted by Savara Inc.'s stock (NASDAQ: SVRA) regarding a class action securities lawsuit. This case seeks to address significant losses faced by investors during the period from March 4, 2024, to May 23, 2025.

Class Definition

The pending lawsuit aims to recoup losses that Savara's investors have incurred due to alleged securities fraud. This encompasses claims that the company misrepresented critical information regarding its product, MOLBREEVI, intended for the treatment of pulmonary alveolar proteinosis. The allegations suggest that the company failed to disclose vital data regarding the product's chemistry, manufacturing, and controls, leading to misstatements about the likelihood of receiving FDA approval.

Individuals may find more details or express their interest in joining the class action by accessing the following link: Savara Inc. Lawsuit Submission. Interested investors can also contact attorney Joseph E. Levi via email or phone for additional assistance.

Case Details

According to the formal complaint, Savara and its representatives made numerous false statements, including:
1. Lack of transparency concerning the critical information that could influence the FDA’s decision on the MOLBREEVI BLA.
2. Underrepresentation of the challenges faced in completing submissions timely, resulting in misinformation relayed to investors.
3. Indications that delays in obtaining regulatory approval might compel the company to seek additional funds, which was not disclosed to shareholders.

These alleged fraudulent activities concerned issues that would materially mislead investors about the financial stability and future prospects of Savara Inc.

What’s Next?

Investors who suffered financial losses during the specified timeframe are encouraged to act promptly. They have a limited window until November 7, 2025, to request the Court to nominate them as lead plaintiffs. It is important to note that being a lead plaintiff is not a prerequisite for participation in potential compensation; all class members may share any recovery achieved through the lawsuit.

No Cost Involved

Participants in this class action will not incur any out-of-pocket expenses or legal fees. Levi & Korsinsky ensures that individuals may seek compensation without worrying about initial financial burdens. Participation in the lawsuit is risk-free for class members.

Why Choose Levi & Korsinsky?

With over two decades of experience, Levi & Korsinsky has established a firm reputation for successfully securing settlements for shareholders. The law firm has previously won numerous high-stakes cases and possesses extensive knowledge in navigating the complexities of securities litigation. For seven consecutive years, they have been ranked among the top securities litigation firms in the United States according to ISS Securities Class Action Services.

For more information and assistance regarding the Savara Inc. class action lawsuit, investors are invited to reach out to Levi & Korsinsky at their New York office:

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

This class action lawsuit serves as an essential opportunity for affected investors to unite and potentially recover losses stemming from Savara Inc.'s alleged misconduct in the securities market.